-25%

PT-141 10 mg

Original price was: 39,99 €.Current price is: 29,99 €. with VAT

PT-141 (bremelanotide) is a cyclic heptapeptide derived from Melanotan-2 that selectively activates the MC4R receptor. Unlike PDE5 inhibitors, it does not act on the vascular system, but rather centrally —in the hypothalamus and limbic system. This is precisely what makes it a subject of research in areas where peripheral mechanisms are insufficient.

Purity ≥ 98% – Each batch verified by HPLC; COA available upon request
10 mg of lyophilized powder, stable for 24 months at −20 °C
Shipped within 48 hours

In stock

Dosage calculator

Quantity discount

Quantity	Price	% Discount
7+	26,99 €	10%
4+	28,49 €	5%

Category: Research on Sun Exposure and Sexual Health

All products are sold exclusively for the purpose of scientific research and development.
The chemical substances may not be used as a medicine, drug, active substance, medical device, cosmetic product, substance for the manufacture of a cosmetic product, or as a substance for human consumption, i.e. as a food or nutritional supplement, or in any other similar way on humans or animals.

All customers MUST be at least 18 years of age to purchase our products.

Laboratory-tested

Fast and Discreet Shipping

Purity Guarantee

98%+

Description

PT-141 10 mg (Bremelanotide) – A Melanocortin Peptide for Research on Sexual Function

⚠️ Legal Notice: PT-141 is intended solely for scientific and research purposes. It is not intended for human use as a medication, dietary supplement, or cosmetic product. Sale is restricted to individuals over the age of 18.

What is PT-141 (Bremelanotide)?

PT-141, scientifically known as bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan-2 (MT-2). It is formed by the enzymatic cleavage of N-terminal acetyl-norleucine from the MT-2 molecule, thereby altering its receptor-binding profile and biological properties.
Unlike most compounds studied in the field of sexual function, PT-141 does not primarily affect the vascular system. Its mechanism of action, which is of scientific interest, is central —it acts through receptors in the brain, specifically in the hypothalamus and the limbic system. It is precisely this property that makes PT-141 a subject of scientific interest in areas where peripheral (vascular) mechanisms are insufficient.
PT-141 belongs to the group of melanocortin peptides—compounds that bind to various subtypes of melanocortin receptors (MC1R through MC5R) and influence a wide range of physiological processes, from skin pigmentation to energy metabolism.

Mechanism of Action in Research

Selective activation of the MC4R receptor

The key mechanism of PT-141 is its selective agonist activity at the melanocortin receptor 4 (MC4R). This receptor is primarily expressed in the hypothalamus and limbic system—areas of the brain that are the focus of research related to the central regulation of sexual motivation and response.
Preclinical studies demonstrate that activation of MC4R in the hypothalamus influences signaling cascades associated with sexual behavior in animal models. This mechanism is independent of peripheral vasodilation, which distinguishes it from PDE5 inhibitors (sildenafil, tadalafil) studied for erectile dysfunction.

Differences from Melanotan-2 and PDE5 inhibitors

PT-141 and its precursor, Melanotan-2 (MT-2), differ significantly in their receptor profiles:

MT-2 activates several receptors at once: MC1R (pigmentation), MC3R (energy metabolism), and MC4R (central sexual function). This also results in significant melanogenesis (darkening of the skin).
In research models, PT-141 exhibits higher selectivity for MC4R with minimal effect on MC1R, which means there is no significant melanogenesis when used in research.

Unlike PDE5 inhibitors, which dilate blood vessels in the genital organs and rely on a peripheral vascular mechanism, PT-141 acts at the central level—through neural pathways in the brain.
Source: Pfaus JG. et al., Current Opinion in Pharmacology (2007); Molinoff PB. et al., Annals of the New York Academy of Sciences (2003)

Regulatory Context – FDA and Vyleesi®

One of the research-related milestones for PT-141 is the FDA’s approval of the drug Vyleesi® (bremelanotide 1.75 mg) in June 2019. This marks the first-ever FDA approval for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women via a central mechanism. Vyleesi® is a subcutaneous injectable formulation of bremelanotide in a pharmaceutical dose.
This approval confirms the scientifically documented mechanism of the MC4R agonist in the central regulation of sexual function and provides an important foundation for further academic research on the molecule.
Important Note: PT-141 10 mg from jacked.sk is a research-grade compound intended exclusively for laboratory and scientific research. It is not identical to the pharmaceutical drug Vyleesi® and is not intended for human therapeutic use.

Areas of Scientific Research on PT-141

Research on Sexual Dysfunction in Women (HSDD)

Clinical studies with bremelanotide (which led to the approval of Vyleesi®) document a statistically significant increase in sexual desire and a reduction in personal distress in premenopausal women diagnosed with HSDD. These clinical data provide a basis for further research on MC4R agonists in the field of sexual neurophysiology.
The RECONNECT study (two parallel Phase 3 trials, n >,1200 women) demonstrated a statistically significant difference compared to placebo in the primary endpoints (FSDS-DAO and FSFI desire domain scores).
Source: Simon JA. et al., Obstetrics & Gynecology (2019)

Preclinical Research on Male Sexual Function

Preclinical studies in rat models have examined the effect of MC4R agonism on erectile function via central pathways. The research documented an increase in the frequency of erectile events following systemic administration of melanocortin agonists compared to control groups. These results suggest that the MC4R in the hypothalamus plays a role in the central regulation of erectile function independent of the peripheral vascular system.
Research in this area continues with the aim of better understanding the neurobiological mechanisms responsible for this response.
Source: Wessells H. et al., Journal of Urology (2000)

Technical Specifications

Parameter	Value
Chemical name	Bremelanotide (PT-141)
Type	Cyclic heptapeptide
Origin	Derived from Melanotan-2 (a metabolite resulting from enzymatic cleavage)
Molecular weight	1,025.2 Da
CAS Number	189691-06-3
Form	Lyophilized (freeze-dried) white powder
Contents per package	10 mg
Purity	≥ 98% (HPLC-verified)
Recommended storage conditions	−20 °C, protected from light and moisture
Stability (lyophilisate)	Up to 24 months at −20 °C
Stability (reconstituted)	Up to 28 days at 4 °C, up to 6 months at −20 °C
Intended Use	For scientific research purposes only

Frequently Asked Questions About PT-141 (Bremelanotide)

What is PT-141, and how is it related to Melanotan-2?

PT-141 (bremelanotide) is a cyclic heptapeptide derived from Melanotan-2. It is formed by enzymatic cleavage of the N-terminal portion of MT-2, which alters its receptor-binding profile. While MT-2 activates several melanocortin receptors, including MC1R (pigmentation), PT-141 exhibits greater selectivity for MC4R—a receptor expressed in brain regions studied in relation to sexual function. This means that, when used for research purposes, PT-141 does not cause significant melanogenesis.

Why is PT-141 of research interest in connection with Vyleesi®?

In 2019, the FDA approved bremelanotide, marketed under the brand name Vyleesi®, for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This is the first FDA approval for this indication with a central (rather than vascular) mechanism of action. This molecule is of particular interest to the scientific community precisely because it demonstrates the validity of MC4R as a therapeutic target in the field of sexual neurophysiology.

How does the mechanism of action of PT-141 differ from that of PDE5 inhibitors?

PDE5 inhibitors (e.g., sildenafil) act peripherally—they dilate blood vessels in the genital organs by inhibiting phosphodiesterase 5 and increasing cGMP levels. PT-141 acts centrally—it activates MC4R receptors in the hypothalamus and limbic system, which are brain regions involved in the regulation of sexual motivation. These two mechanisms are independent of one another, and preclinical research is investigating their potential complementarity.

What is the purity of the PT-141 sold on jacked.sk?

PT-141 from jacked.sk has a purity of ≥98%, verified by HPLC (High-Performance Liquid Chromatography). Each batch is tested before shipment. A Certificate of Analysis (COA) is available upon request.

How should freeze-dried PT-141 be stored?

Store unopened packages at −20 °C, protected from light and moisture. After reconstitution with bacteriostatic water, store at 4 °C (for up to 28 days) or refreeze at −20 °C (for up to 6 months). We recommend avoiding repeated thawing and refreezing, which may reduce the stability of the peptide.

Is PT-141 legal in Slovakia?

PT-141 (bremelanotide) is not listed as a controlled substance or a prohibited drug in the EU. In Slovakia, its purchase and possession for scientific research purposes are legal. Sales are intended exclusively for scientists and researchers. Jacked.sk sells PT-141 solely for scientific and research purposes, not for human use.

⚠️ Warning – Intended exclusively for research purposes

All products sold on jacked.sk are intended EXCLUSIVELY for scientific research purposes. They are not intended for use as a medicine, drug, dietary supplement, or cosmetic product, nor for human or veterinary use. The results cited in the descriptions are based on preclinical studies (in vitro, animal models) and cannot be automatically extrapolated to human use. Sale restricted to individuals over the age of 18. By purchasing this product, the customer confirms that they are a professional researcher and will use the product solely in accordance with applicable laws.